Articles

KIPO Sequence Listing Requirements: Filing Patents in South Korea

If you are working in the field of biotechnology, pharmaceuticals, or molecular biology, and you plan to protect your invention in South Korea, understanding the KIPO sequence listing requirements is not optional. It is essential.

The Korean Intellectual Property Office, commonly known as KIPO, oversees the patent filing process in South Korea. When your patent application involves nucleotide or amino acid sequences, you must follow a specific set of rules for disclosing those sequences. These rules are what we call the kipo sequence listing requirements, and failing to meet them can result in delays, objections, or even rejection of your application.

This article is designed to walk you through everything you need to know, in a clear and simple manner, so that you can file your patent in South Korea with confidence.

What Is a Sequence Listing and Who Needs It?

A sequence listing is a standardized document that discloses all nucleotide sequences (DNA/RNA) and amino acid sequences (proteins) that are claimed or referred to in a patent application. Think of it as a structured inventory of all the biological sequences that form the core of your invention.

Any patent applicant whose invention includes sequences of ten or more nucleotides, or four or more amino acids, must include a proper sequence listing as part of their application. This applies globally, and South Korea is no exception. The kipo sequence listing requirements are built upon both international frameworks and KIPO-specific national rules.

The ST.26 Standard: The Foundation of KIPO Sequence Listing Requirements

One of the most important things to understand about the current kipo sequence listing requirements is the adoption of the WIPO ST.26 standard. From July 1, 2022, WIPO officially replaced the older ST.25 standard with ST.26 across all member countries, including South Korea.

KIPO aligned itself with this global transition, which means all sequence listings filed at KIPO must now be prepared in the ST.26 format. The ST.26 standard uses XML-based formatting, replacing the older plain-text format used under ST.25. This shift brought several important changes that every applicant must keep in mind.

Under ST.26, sequences are submitted as a single XML file. The file must be generated using WIPO’s free tool called WIPO Sequence, which ensures proper formatting and validation before submission.

Key KIPO Sequence Listing Requirements: What You Must Know

This is where the practical guidance begins. Below are the core kipo sequence listing requirements that every applicant must comply with.

XML Format Only: The sequence listing must be prepared as a valid XML file following the ST.26 schema. KIPO does not accept plain-text sequence listings for new applications filed after July 2022.
Use of WIPO Sequence Software: Applicants are strongly encouraged (and in practice expected) to use the WIPO Sequence tool to generate the XML file. This ensures the file passes validation checks before submission.
Language Requirements: KIPO is a national office where Korean is the official language. The sequence listing XML file must include the application details in Korean, or a Korean translation must accompany the application if originally filed in another language.
No Paper Submission: Sequence listings in South Korea must be submitted electronically. Paper submissions are not accepted for sequence listings.
File Size and Submission Portal: The listing must be submitted through KIPO’s online e-filing system. Large files may require special handling, and applicants should check the maximum file size allowed at the time of submission.
Incorporation by Reference: The sequence listing forms a part of the patent application and must be properly incorporated by reference in the description. Simply attaching the file is not enough; the description must reference it clearly.
Consistency Between Sequences and Claims: Every sequence mentioned in the claims and description must appear in the sequence listing. Any mismatch between the sequences cited in the text and those listed in the XML file can trigger an official objection.

Filing Through the PCT Route vs. Direct National Phase at KIPO

Many international applicants enter South Korea through the Patent Cooperation Treaty (PCT) route. If you filed a PCT application using the ST.26 standard and included a compliant sequence listing, the same file generally applies when entering the national phase at KIPO. However, there are important nuances.

When entering the Korean national phase, you must ensure that your sequence listing has been filed with the International Bureau and that KIPO has access to it. If your PCT application was filed under the older ST.25 standard, you may need to convert it to ST.26 format for the Korean national phase, depending on the filing date and applicable transitional provisions.

Applicants should always verify with a registered Korean patent attorney or agent whether additional steps are needed for their specific situation, especially for transitional applications.

Common Mistakes to Avoid

Understanding the kipo sequence listing requirements also means knowing what can go wrong. Here are some of the most frequent errors that cause delays:

Submitting a sequence listing in the old ST.25 text format instead of ST.26 XML.
Forgetting to incorporate the sequence listing by reference in the patent description.
Including sequences in the description or claims that are not listed in the XML file.
Filing without Korean language compliance when required.
Using third-party software that does not fully comply with WIPO’s ST.26 schema.

Final Thoughts on KIPO Sequence Listing Requirements

Meeting the kipo sequence listing requirements is a critical step for any biotech or pharmaceutical company seeking patent protection in South Korea. The move to ST.26 has made the process more standardized globally, but national rules at KIPO still add specific layers that you must address carefully.

Whether you are filing directly or through the PCT route, take the time to validate your sequence listing using WIPO’s official tool, ensure language compliance, and work with a qualified Korean patent professional. A well-prepared sequence listing not only satisfies KIPO’s formal requirements but also strengthens the overall quality and defensibility of your patent.

For more expert guidance on sequence listing preparation and international patent filing, visit The Sequence Listing and explore our full range of resources and services.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.